DNB Asset Management AS Boosts Stake in Abbott Laboratories $ABT

DNB Asset Management AS raised its holdings in shares of Abbott Laboratories (NYSE:ABT) by 3.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 479,706 shares of the healthcare product maker’s stock after buying an additional 15,578 shares during the quarter. DNB Asset Management AS’s holdings in Abbott Laboratories were worth $60,102,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. IMG Wealth Management Inc. grew its position in Abbott Laboratories by 63.0% during the fourth quarter. IMG Wealth Management Inc. now owns 308 shares of the healthcare product maker’s stock worth $39,000 after buying an additional 119 shares in the last quarter. Isthmus Partners LLC purchased a new position in Abbott Laboratories during the fourth quarter worth about $328,000. Phoenix Financial Ltd. lifted its stake in Abbott Laboratories by 64.1% during the fourth quarter. Phoenix Financial Ltd. now owns 50,704 shares of the healthcare product maker’s stock worth $6,352,000 after purchasing an additional 19,798 shares during the last quarter. Thrivent Financial for Lutherans lifted its stake in Abbott Laboratories by 24.3% during the fourth quarter. Thrivent Financial for Lutherans now owns 246,586 shares of the healthcare product maker’s stock worth $30,931,000 after purchasing an additional 48,286 shares during the last quarter. Finally, Maxele Advisors LLC lifted its stake in Abbott Laboratories by 6.5% during the fourth quarter. Maxele Advisors LLC now owns 11,406 shares of the healthcare product maker’s stock worth $1,429,000 after purchasing an additional 700 shares during the last quarter. 75.18% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Abbott Laboratories news, Director Daniel J. Starks purchased 10,000 shares of the stock in a transaction on Monday, April 27th. The stock was acquired at an average price of $92.65 per share, with a total value of $926,500.00. Following the transaction, the director directly owned 6,751,103 shares of the company’s stock, valued at approximately $625,489,692.95. This trade represents a 0.15% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Philip P. Boudreau purchased 2,200 shares of the stock in a transaction on Thursday, April 23rd. The shares were acquired at an average cost of $91.50 per share, with a total value of $201,300.00. Following the transaction, the chief financial officer directly owned 2,200 shares in the company, valued at $201,300. The trade was a ? increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have sold a total of 3,055 shares of company stock worth $353,097 in the last 90 days. 0.46% of the stock is currently owned by company insiders.

Abbott Laboratories Trading Down 0.5%

NYSE ABT opened at $84.49 on Friday. Abbott Laboratories has a 1-year low of $81.97 and a 1-year high of $139.06. The company has a current ratio of 1.39, a quick ratio of 1.01 and a debt-to-equity ratio of 0.56. The stock has a 50-day moving average of $99.02 and a 200-day moving average of $113.35. The firm has a market cap of $147.16 billion, a PE ratio of 23.67, a price-to-earnings-growth ratio of 1.42 and a beta of 0.65.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share for the quarter, beating analysts’ consensus estimates of $1.14 by $0.01. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The company had revenue of $11.16 billion during the quarter, compared to analyst estimates of $10.99 billion. During the same quarter in the previous year, the company posted $1.09 EPS. Abbott Laboratories’s revenue for the quarter was up 7.8% on a year-over-year basis. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. As a group, sell-side analysts forecast that Abbott Laboratories will post 5.48 EPS for the current year.

Abbott Laboratories Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th were paid a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a dividend yield of 3.0%. The ex-dividend date of this dividend was Wednesday, April 15th. Abbott Laboratories’s payout ratio is 70.59%.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on ABT shares. Stifel Nicolaus dropped their price target on Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating for the company in a research note on Friday, April 17th. Leerink Partners dropped their price target on Abbott Laboratories from $119.00 to $106.00 and set a “market perform” rating for the company in a research note on Tuesday, April 21st. Benchmark dropped their price target on Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating for the company in a research note on Friday, April 17th. Daiwa Securities Group lowered Abbott Laboratories from an “outperform” rating to a “neutral” rating and set a $92.00 price target for the company. in a research note on Wednesday, April 22nd. Finally, Raymond James Financial dropped their price target on Abbott Laboratories from $130.00 to $115.00 and set an “outperform” rating for the company in a research note on Friday, April 17th. Two analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat.com, Abbott Laboratories currently has an average rating of “Moderate Buy” and an average price target of $119.43.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.